141 related articles for article (PubMed ID: 30510970)
1. NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
Huang H; Guma SR; Melamed J; Zhou M; Lee P; Deng FM
Am J Clin Exp Urol; 2018; 6(5):182-188. PubMed ID: 30510970
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of NKX 3.1 and HOXB 13 in bone metastases originating from prostatic carcinoma among the Egyptian males.
Abouhashem NS; Salah S
Pathol Res Pract; 2020 Oct; 216(10):153221. PubMed ID: 32979741
[TBL] [Abstract][Full Text] [Related]
3. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
4. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
Jia L; Jiang Y; Michael CW
Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
7. Expression of NKX3.1, Prostatic Specific Antigen and Prostatic Specific Alkaline Phosphatase in Cytology Specimens of Metastatic Prostatic Carcinoma.
Wang M; Abi-Raad R; Adeniran AJ; Cai G
J Clin Transl Pathol; 2021 Dec; 1(1):16-20. PubMed ID: 35265947
[TBL] [Abstract][Full Text] [Related]
8. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
11. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
12. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma.
Bernacki KD; Fields KL; Roh MH
Diagn Cytopathol; 2014 Jul; 42(7):570-5. PubMed ID: 24273068
[TBL] [Abstract][Full Text] [Related]
13. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.
Oh WJ; Chung AM; Kim JS; Han JH; Hong SH; Lee JY; Choi YJ
J Pathol Transl Med; 2016 Sep; 50(5):345-54. PubMed ID: 27498545
[TBL] [Abstract][Full Text] [Related]
14. NKX3.1 immunohistochemistry is highly specific for the diagnosis of mesenchymal chondrosarcomas: experience in the Australian population.
Ramanayake N; Vargas AC; Talbot J; Bonar F; Wong DD; Wong D; Mahar A; Karim R; Luk PP; Selinger C; Sioson L; Gill AJ; Maclean F
Pathology; 2021 Oct; 53(6):705-712. PubMed ID: 33640159
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
[TBL] [Abstract][Full Text] [Related]
16. NKX3.1 Identifies Prostatic Origin of Dural Metastasis in the Setting of Negative Prostate-Specific Antigen Stain.
Shen JZ; Memon AA; Hackney JR; Sotoudeh H; Fathallah-Shaykh H
Neurohospitalist; 2020 Oct; 10(4):314-317. PubMed ID: 32983354
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.
Yin M; Dhir R; Parwani AV
Diagn Pathol; 2007 Oct; 2():41. PubMed ID: 17963516
[TBL] [Abstract][Full Text] [Related]
19. Prostatic carcinoma metastatic to bone: sensitivity and specificity of prostate-specific antigen and prostatic acid phosphatase in decalcified material.
Shah NT; Tuttle SE; Strobel SL; Gandhi L
J Surg Oncol; 1985 Aug; 29(4):265-8. PubMed ID: 2417056
[TBL] [Abstract][Full Text] [Related]
20. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.
Hupe MC; Philippi C; Roth D; Kümpers C; Ribbat-Idel J; Becker F; Joerg V; Duensing S; Lubczyk VH; Kirfel J; Sailer V; Kuefer R; Merseburger AS; Perner S; Offermann A
Front Oncol; 2018; 8():623. PubMed ID: 30619757
[No Abstract] [Full Text] [Related]
[Next] [New Search]
